As Europe learns to live with the pandemic, the development and swift global deployment of safe and effective vaccines against COVID-19 remains an essential element in the eventual solution to the public health crisis. In this context, the Commission is working to ensure that there will be access to safe vaccines across Europe, and encourages […]
Read More
Remdesivir: European Commission guarantees access
On 28th July the European Commission signed a contract with the pharmaceutical company Gilead to guarantee treatment doses of Veklury, which is the trade name of remdesivir. Veklury was the first drug authorised on an EU level for the treatment of COVID-19. From early August, batches of Veklury will be made available to Member States […]
Read MoreCovid-19: Support for vaccine research with additional €100 million
The Coalition for Epidemic Preparedness Innovations (CEPI), a global partnership created in 2017 to develop vaccines to prevent future epidemics, has launched a call to support the rapid development and global manufacture of COVID-19 vaccines. The EU will co-fund the call with €100 million. The EU support is part of the pledge to invest €1 billion from Horizon […]
Read More
Commission and EIB provide CureVac with a €75 million financing for vaccine development and expansion of manufacturing
The European Investment Bank (EIB) and CureVac, a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on optimised mRNA, entered into a €75 million loan agreement to support the Company’s ongoing development of vaccines against infectious diseases, including its vaccine candidate CVnCoV aimed at preventing SARS-CoV-2 infections. El préstamo, además, apoyará los […]
Read MoreEuropean Commission unveils EU vaccines strategy
The European Commission has presented a European strategy to accelerate the development, manufacture and deployment of vaccines against COVID-19. An effective and safe vaccine against the virus is our best bet for a permanent solution to the pandemic. The Commission will support efforts to accelerate the development and availability of safe and effective vaccines within […]
Read More
Statistics: COVID-19 evolution in Eastern Mediterranean – May
Infections by country As of 29 May 2020, the countries with the highest number of registered cases are Iran (1,721,926 cases), Saudi Arabia (438,238), Pakistan (141,779), Qatar (89,976) and the United Arab Emirates (86,943). However, in terms of population, the countries with the highest number of infections are Qatar (2342 cases per 100,000 population), Kuwait […]
Read More
First COVID-19 treatment recommended for EU authorization
EMA’s human medicines committee (CHMP) has recommended granting conditional marketing authorisation to Veklury (remdesivir) for the treatment of COVID-19 in adults and adolescents from 12 years of age with pneumonia who require supplemental oxygen Remdesivir is the first medicine against COVID-19 to be recommended for authorisation in the EU. Data on remdesivir were assessed in […]
Read More
Statistics: COVID-19 evolution in the Western Pacific – May
Infections by country As of 29 May 2020, the countries with the most cases registered are China (84,432 cases), Singapore (41,216), the Philippines (27,238), Japan (17,530) and South Korea (12,198). However, if we look at the number of inhabitants, the countries with the most infections are Singapore (with 712 cases per 100,000 inhabitants), Australia (36), […]
Read More
Global regulators discuss data requirements for phase 3 trials of COVID-19 vaccines
Under the umbrella of the International Coalition of Medicines Regulatory Authorities (ICMRA), international regulators discussed COVID-19 vaccine development and the necessary evidence required for regulatory decision-making at the second regulatory workshop on COVID-19 vaccines. The meeting was jointly organised by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) on 22 June […]
Read More